The pharmaceutical firm Regeneron announced it was entering the late stages of its human clinical trials investigating a drug to both treat and prevent COVID-19.
The drug, called REGN-COV2, is a combination of two antibodies that block the coronavirus’ “spike protein”, which it uses to invade human cells.
The company is moving to the final Phase 3 stage of a trial to determine if its drug can prevent infection among people recently exposed to the virus – for example through a person in their household. This trial, run jointly with the US National Institute of Allergy and Infectious Diseases (NIAID), is expected to enroll 2,000 patients in the US.
“We are pleased to collaborate with NIAID to study REGN-COV2 in our quest to further prevent the spread of the virus with an antiviral antibody cocktail that could be available much sooner than a vaccine,” said Regeneron President George Yancopoulos.